drugset / Trial / NCT02232555

Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain

NCT02232555

Phase 3 Completed 327 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to investigate the efficacy of duloxetine versus placebo on pain in outpatients with major depressive disorder (MDD): change in Brief Pain Inventory Short Form (BPI-SF) 24-hour average pain score from baseline over the 8 weeks of treatment

Timeline

Start
2005-05
Primary completion
2006-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg